Senseonics Holdings, Inc. (SENS) Stock Price & Analysis
Senseonics Holdings, Inc. (SENS) is trading at USD 7.58, up 2.43% today, as of October 23, 2026 at 16:58 UTC (US market open; quotes may be delayed), according to Nexqual market data.
SENS last closed at USD 7.58; today's session has ranged USD 7.25–7.59 on volume of 245,758 shares. Market capitalization is —, with a 52-week range of USD 4.79–10.64 (NMS). Source: Nexqual, retrieved October 23, 2026 at 17:01 UTC.
Also available as compact Markdown for AI agents: nexqual.com/SENS.md
Key facts (SENS)
- Last four reported quarters (through Jun 30, 2026): revenue $48.5M, net income -$109M (-225.3% margin), free cash flow -$96.8M (SEC filings).
- Total return with dividends: 1Y +3.1% vs S&P 500 +14.6%; 5Y -89.2% vs S&P 500 +77.3%.
- Next earnings: 2026-11-09, EPS estimate USD -0.52, revenue estimate $16.2M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (SENS)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $13.7M | $16.4M | $22.4M | $22.5M | $35.3M | $48.5M |
| Gross profit | -$811K | $2.7M | $3.1M | $533K | $15.8M | — |
| Operating income | -$57.2M | -$68.6M | -$75.6M | -$74.8M | -$68.3M | -$108M |
| Net income | -$302M | $142M | -$60.4M | -$78.6M | -$69.1M | -$109M |
| EPS (diluted) | -$14.40 | -$2.20 | -$2.20 | -$2.50 | -$1.66 | — |
| Free cash flow | -$56.3M | -$66.6M | -$70.5M | -$62.7M | -$60.2M | -$96.8M |
| Gross margin | -5.9% | 16.6% | 13.8% | 2.4% | 44.7% | — |
| Operating margin | -418.1% | -418.7% | -337.7% | -333.0% | -193.8% | -223.2% |
| Net margin | -2211.9% | 867.2% | -269.7% | -349.8% | -196.0% | -225.3% |
| Revenue growth | +176.3% | +19.8% | +36.6% | +0.4% | +56.9% | — |
| Cash + short-term investments | $182M | $156M | $110M | $74.6M | $94.0M | — |
| Total debt | $59.8M | $56.4M | $41.2M | $34.7M | $35.6M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (SENS)
Analysts (SENS)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-07 | Barclays | Initiated | Equal-Weight | $10 |
| 2026-07-15 | Mizuho | Target lowered | Outperform | $20 → $18 |
Total return (dividends reinvested) (SENS)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +3.1% | -89.2% |
| S&P 500 (SPY) | +14.6% | +77.3% |
| Per year | +3.1% | -35.9% |
| Volatility (annualized) | 77.6% | 86.9% |
| Max drawdown | -41.8% (Feb 2026→Jul 2026) | -93.7% (Nov 2021→Jul 2026) |
SENS revenue by region (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| United States | $12.6M | 86.8% | +154.2% |
| Non Us | $1.9M | 13.2% | +12.2% |
| Total revenue | $14.5M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
SENS suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Ascensia Diabetes Care Holdings | “As described in detail below, in August 2020, we entered into a collaboration and commercialization agreement ("Commercialization Agreement"), with Ascensia pursuant to which we granted Ascensia the exclusive right to distribute Eversense worldwide, with certain initial exceptions.” |
| Partner | Hercules Capital, Inc. (HTGC) | “On September 8, 2023, the Company entered into the "Loan and Security Agreement with Hercules Capital, Inc. and its managed fund (collectively, the "Lenders"), pursuant to which the Lenders have to make available to Senseonics up to $50.0 million in senior secured term loans (the "Term Loan Facility"), consisting of (i) an initial term loan of $25.0 million (the "Tranche 1 Loan"), which was funded on the Effective…” |
Quoted from the company's 10-K filed Mar 2, 2026.
SENS customer concentration
In the period ended Jun 30, 2026, 2 direct customers each accounted for at least 10% (57.7%, 12.5%) of revenue, per the company's 10-Q filed Aug 6, 2026. The company does not name them.
SENS company outlook (results filed Aug 6, 2026)
- “Senseonics is raising its full-year 2026 global net revenue guidance to $62 million to $66 million from $60 million to $64 million, representing year-over-year growth of 76% to 87%, and is raising its full-year gross margin guidance to a range of 58% to 61% from its prior range of 55% to 58%.”
- “The Company's outlook continues to reflect the ongoing roll-out of Eversense 365 outside the United States, planned direct-to-consumer marketing investment, the status of other sales and marketing initiatives, and utilization of the patient assistance programs for Eversense 365.”
Quoted word-for-word from the SEC 8-K results press release.
SENS analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.52 | $-0.60 | -13.3% | $16.2M | 7 |
| Next quarter (ends Dec 2026) | $-0.46 | $-0.55 | -16.2% | $21.8M | 7 |
| Current fiscal year (ends Dec 2026) | $-2.29 | $-2.45 | -6.7% | $64.2M | 7 |
| Next fiscal year (ends Dec 2027) | $-1.95 | $-2.19 | -10.8% | $100.0M | 7 |
SENS options: expected move
Options price a move of about ±16.3% (±$1.20) by Nov 20, 2026, which includes earnings on Nov 9, 2026. Over the last 8 reports the stock moved ±12.7% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 74.7% | ±16.3% |
| Jan 15, 2027 | 84 | 61.6% | ±23.7% |
| Apr 16, 2027 | 175 | 72.0% | ±39.6% |
30-day implied volatility 80% vs 59.4% realized over the last 30 trading days. Put/call ratio (volume) 0.36. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 17:01 UTC)
| Price | USD 7.58 |
|---|---|
| Change | ▲ 2.43% (up) |
| Previous Close | USD 7.58 |
| Open | USD 7.58 |
| Day Range | USD 7.25 – 7.59 |
| 52-Week Range | USD 4.79 – 10.64 |
| Volume | 245,758 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (SENS)
Nexqual's technical model rates SENS "SELL" based on 1 bullish and 5 bearish signals across 128 daily candles, as of October 23, 2026 at 17:01 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 34.66 (neutral) |
| vs SMA50 | Below (USD 9.15) |
| MACD | -0.43 (negative) |
Earnings (SENS)
| Next Earnings Date | 2026-11-09 |
|---|---|
| EPS Estimate | USD -0.52 |
| Revenue Estimate | $16.20M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.63 vs est -0.62 ▼ miss |
| 2026-03-31 | USD -0.71 vs est -0.7 ▼ miss |
| 2025-12-31 | USD -0.46 vs est -0.43 ▼ miss |
| 2025-09-30 | USD -0.43 vs est -0.4 ▼ miss |
Source: Nexqual, October 23, 2026 at 17:01 UTC.
Financials & Fundamentals (SENS)
| Total Revenue | $48.55M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +117.80% |
| Gross Margin | +54.87% |
| Operating Margin | -248.48% |
| Profit Margin | -225.34% |
| ROE | -118.24% |
| Debt / Equity | 0.7 |
| Current Ratio | 6.75 |
| Total Cash | $142.66M |
| Total Debt | $62.82M |
Source: Nexqual, October 23, 2026 at 17:01 UTC.
Ownership (SENS)
| Insider Ownership | +9.87% |
|---|---|
| Institutional Ownership | +39.64% |
| Shares Outstanding | 52.87M |
| Float | 43.67M |
| Short % of Float | +10.43% |
Source: Nexqual, October 23, 2026 at 17:01 UTC.
From Senseonics Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-03-02)
Key Strengths & Strategy (as disclosed to the SEC)
- We have reached approximately 300 million covered lives in the U.S. through positive insurance payor coverage decisions including UnitedHealthcare, the largest healthcare insurance company in the U.S.
- Following the results of the PROMISE trial, on September 30, 2020, a Premarket Approval Application Supplement, or PMA supplement to extend the wearable life of the Eversense CGM System to six months was submitted to the FDA.
- Our mobile app is a software application that runs on both platforms; iOS mobile devices, including iPhones, iPads and Apple Watches, and Android mobile devices.
- Our contract manufacturers are all recognized in their field for their competency to manufacture the respective portions of our system and have quality systems established that meet FDA and, to the extent required, international regulatory requirements.
Partnerships
- In connection with the execution of the Master Asset Purchase Agreement, the Company and Ascensia also entered into the A&R Commercialization Agreement on December 31, 2025, which amended and restated that certain Collaboration and Commercialization Agreement, dated August 9, 2020, as amended to date (the "Existing Commercialization Agreement").
- In 2022, we announced a collaboration with NPG designed to expand U.S. patient access to Eversense by providing additional convenient in-office and at-home sensor insertion options utilizing NPG's broad network in approximately 30 states.
Legal & Regulatory Risks (Item 1A, quoted)
- Any adverse event involving our products could result in future voluntary corrective actions, such as recalls or customer notifications, or regulatory agency action, which could include inspection, mandatory recall or other enforcement action.
- Our activities, including our research, sales and marketing, training programs, and patient reimbursement support activities, and relationships with Eon Care PCs, may be subject to scrutiny under these laws.
- Future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities' systems and technologies.
- We may expend significant resources or modify our business activities, including our clinical trial activities, to try to protect against security incidents, and have in the past.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BNGO | Bionano Genomics, Inc. | USD 1.13 | ▼ 4.24% |
| NNDM | Nano Dimension Ltd. | USD 1.35 | ▼ 2.46% |
| OCGN | Ocugen, Inc. | USD 0.75 | ▼ 4.81% |
| CTRM | Castor Maritime Inc. | USD 1.63 | ▲ 2.52% |
| GEVO | Gevo, Inc. | USD 1.16 | ▲ 1.67% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 17:01 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt